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Introduction {#sec1}
============

The MYC family of transcription factors (MYC, N-MYC, and L-MYC) has been causally implicated in the development of multiple human tumors ([@bib11]). MYC proteins bind to virtually all promoters with an open chromatin structure as well as to thousands of enhancers ([@bib52], [@bib40], [@bib25], [@bib33]). They stimulate transcription of large groups of genes encoding, among others, proteins involved in protein translation, cell cycle progression, and intermediary metabolism and repress transcription of genes encoding cell cycle inhibitory proteins as well as proteins involved in cell adhesion and differentiation ([@bib11]). In some settings, MYC proteins act as "general amplifiers" that enhance transcription of all actively transcribed protein-coding genes ([@bib33], [@bib25]).

During early transcription, RNA polymerase II (Pol II) goes through a series of intermediate states that begin with the formation of a closed promoter complex and end with the release of Pol II from a promoter-proximal pause position into productive elongation ([@bib29]). To enhance transcription, MYC proteins promote both recruitment of Pol II to the promoter and its subsequent release into elongation ([@bib36], [@bib20], [@bib52]). Escape from the promoter and pause release of Pol II are controlled by sequential phosphorylation of Ser5 and Ser2 in the C-terminal domain of Pol II and activation of MYC promotes phosphorylation at both sites ([@bib21], [@bib36], [@bib52], [@bib7]). Known protein-protein interactions of MYC include the association with MAX, which is required for binding to DNA ([@bib3]), the NuA4 histone acetylase complex ([@bib28]), the p400 and BPTF chromatin-remodeling complexes ([@bib38], [@bib15]), and the PAF1C elongation complex ([@bib20]). How MYC engages its different cofactors to promote elongation and how this process is regulated is largely unknown.

Deregulated expression of N-MYC is characteristic for subentities of pediatric neuroblastoma and medulloblastoma as well as for adult neuroendocrine and some hematopoietic malignancies ([@bib2]). Like all MYC proteins, N-MYC is rapidly turned over via the ubiquitin/proteasome system ([@bib44]). The SCF^FBXW7^ ubiquitin ligase recognizes a phosphodegron that is part of a conserved domain called MYCBoxI ([@bib53]). Replacing two phosphoresidues, T58 and S62, with alanine stabilizes N-MYC ([@bib35]). S62 is phosphorylated by cyclin-dependent kinases and primes phosphorylation of T58 by GSK3, resulting in cell cycle- and growth factor-dependent proteasomal turnover of N-MYC ([@bib5], [@bib44]).

In multiple tumor entities, N-MYC is stabilized by complex formation with Aurora-A ([@bib35], [@bib12]). Aurora-A is a serine/threonine kinase that is best known for its role in centrosome function and mitosis ([@bib27]). Aurora-A binds to N-MYC directly via two domains that flank the SCF^FBXW7^ phosphodegron and antagonizes degradation of N-MYC by SCF^FBXW7^ ([@bib35], [@bib37]). Although stabilization of N-MYC does not require Aurora-A catalytic activity, Aurora-A inhibitors that distort the kinase domain dissociate the N-MYC/Aurora-A complex and destabilize N-MYC ([@bib37]). These inhibitors show therapeutic efficacy in N-MYC-driven tumor models and are being tested in human patients ([@bib14]). We have now analyzed protein complexes of N-MYC to understand how N-MYC controls Pol II function and how association with Aurora-A impacts N-MYC function.

Results {#sec2}
=======

Complexes of N-MYC with TFIIIC, TOP2A, and RAD21 {#sec2.1}
------------------------------------------------

To identify protein complexes of N-MYC in neuroblastoma cells, we used SH-EP cells, which do not express endogenous N-MYC. Using retroviral infection, we stably expressed HA-tagged wild-type (WT) N-MYC (N-MYC~wt~) or N-MYCT58AS62A (N-MYC~mut~) ([Figure 1](#fig1){ref-type="fig"}A). Immunoblots showed that levels of N-MYC in infected cells were comparable with those found in a *MYCN*-amplified neuroblastoma cell line, IMR-32 ([Figure 1](#fig1){ref-type="fig"}A). We then performed mass spectrometry of complexes recovered after immunoprecipitation with α-hemagglutinin (α-HA) antibodies and elution with a HA peptide using label-free quantification ([Figure 1](#fig1){ref-type="fig"}B; [Table S1](#mmc2){ref-type="supplementary-material"}). The analysis confirmed multiple well-validated interactions of N-MYC or MYC proteins, including interactions with TRRAP, p400, BPTF, MAX, Aurora-A, and CDC73 ([Figure S1](#mmc1){ref-type="supplementary-material"}A). In addition, the analysis identified interactions with 5 of 6 subunits of the TFIIIC complex and topoisomerases IIA and IIB (TOP2A and TOP2B). TFIIIC is both a general transcription factor of RNA polymerase III and an architectural protein that is localized at the border of topological domains ([@bib9], [@bib50]). TOP2A has been implicated in relieving transcription-induced supercoiling at highly active promoters ([@bib24]). We speculated, therefore, that these interactions may identify effector functions of N-MYC.Figure 1Complexes of N-MYC with TFIIIC, TOP2A, RAD21, and Aurora-A(A) Immunoblot documenting levels of ectopically expressed (exo) N-MYC~wt~ and N-MYC~mut~ proteins in stably infected SH-EP neuroblastoma cells relative to endogenous N-MYC (endo) of IMR-32 *MYCN*-amplified neuroblastoma cells. Where indicated, ectopically expressed proteins carry an N-terminal HA tag (NT HA); hence, their molecular weight is slightly larger than that of the endogenous protein (n = 2).(B) Results of mass spectrometry of α-HA immunoprecipitates of N-MYC~wt~ and N-MYC~mut~ complexes. The axes show the normalized ratio of peptides recovered in an α-HA immunoprecipitation from cells expressing N-MYC~wt~ or N-MYC~mut~ relative to an α-HA immunoprecipitation (IP) from control cells. Dot size represents the MaxQuant protein scores, which indicates the reliability of protein identification ([@bib8]).(C) Immunoblots of α-N-MYC (left) and α-TFIIIC5 (right) immunoprecipitates from IMR-32 cells. The input corresponds to 1% of the amount used for the precipitation. Where indicated, ethidium bromide (EtBr) was added to a final concentration of 1 μg ml^−1^ to disrupt DNA-dependent interactions. Non-specific immunoglobulin G (IgG) was used for control immunoprecipitations (n = 3).(D) Pull-down assays from cell lysates documenting binding of TFIIIC5 and RAD21 to FLAG-tagged peptides spanning the indicated amino acids of the N-MYC N terminus. The input corresponds to 0.6% of the amount used for the precipitation (n = 2). The graph at the bottom visualizes the binding of the different N-MYC peptides. I/II indicate N-MYC sequences that mediate binding.(E) Immunoblots of α-N-MYC (left) and α-Aurora-A (right) immunoprecipitates from *MYCN*-amplified IMR-5 cells. The input corresponds to 1% of the amount used for the precipitation. Non-specific IgG was used for control immunoprecipitates (n = 4).(F) Pull-down assays from cell lysates documenting binding of TFIIIC5 and RAD21 to FLAG-tagged N-MYC peptides spanning amino acids 1--137 upon competition with Aurora-A. Recombinant Aurora-A protein was added in a concentration-dependent manner from 0.25 to 5 molar equivalents (Aurora-A/N-MYC peptide). 5 molar equivalents of glutathione-S-transferase (GST) were used as a control (n = 3).See also [Figure S1](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc2){ref-type="supplementary-material"}. n indicates the number of independent biological replicas for each experiment.

Immunoprecipitations using α-HA antibodies confirmed that TFIIIC and TOP2A were present in immunoprecipitates from cells expressing N-MYC but not in control immunoprecipitates from cells not expressing HA-tagged N-MYC ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Parallel mass spectrometry demonstrated the presence of 5 of 6 subunits of TFIIIC and TOP2A in α-N-MYC immunoprecipitates but not in control immunoprecipitates from *MYCN*-amplified neuroblastoma cells ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Multiple subunits of TFIIIC and TOP2A were also detected in α-HA precipitates from U2OS cells expressing HA-tagged MYC but not control immunoprecipitates, arguing that MYC, like N-MYC, associates with these proteins ([Figure S1](#mmc1){ref-type="supplementary-material"}D); this is consistent with a previous mass spectrometric analysis ([@bib23]). Using an antibody that recognizes TFIIIC5, we confirmed that TFIIIC associates with endogenous N-MYC and, albeit more weakly, with TOP2A as well as TOP2B in *MYCN*-amplified neuroblastoma cells ([Figure 1](#fig1){ref-type="fig"}C; [Figure S1](#mmc1){ref-type="supplementary-material"}E). Notably, interactions of N-MYC with TFIIIC5 and TOP2A were also observed in the presence of ethidium bromide (EtBr), which disrupts DNA-dependent interactions ([Figure 1](#fig1){ref-type="fig"}C). This observation precludes the possibility that the interactions are indirectly mediated by DNA.

To identify domains of N-MYC that interact with TFIIIC and TOP2A, we performed pull-down assays from cell lysates incubated with recombinant FLAG-tagged peptides covering fragments of the N-MYC N terminus ([Figure 1](#fig1){ref-type="fig"}D). These assays showed that residues 1--137 are sufficient for binding to TFIIIC and suggested that two regions of N-MYC that flank MYCBoxI, but not MYCBoxI itself (peptides 46--89), mediate binding to TFIIIC. Controls established that an equimolar amount of an unrelated FLAG-tagged protein (heterogeneous nuclear ribonucleoprotein \[hnRNP\], amino acids 330--463) does not bind TFIIIC5 (E.L., unpublished data). In parallel assays, we were unable to demonstrate that residues 1--137 of N-MYC are sufficient for binding to TOP2A (E.L., unpublished data). Previous work has demonstrated that TFIIIC co-localizes and associates with cohesin and condensin complexes in different organisms ([@bib50], [@bib10]), prompting us to search for the presence of these complexes in N-MYC immunoprecipitates. Indeed, peptides of the kleisin component of the cohesin complex, RAD21, were found in the mass spectrometry analysis ([Table S1](#mmc2){ref-type="supplementary-material"}), and we confirmed that both N-MYC expressed in SH-EP cells and endogenous N-MYC in *MYCN*-amplified IMR-5 cells associates with RAD21 ([Figure 1](#fig1){ref-type="fig"}E; [Figure S1](#mmc1){ref-type="supplementary-material"}B). Mapping of the interaction to the N-MYC N terminus showed the same binding pattern as TFIIIC, suggesting that they co-exist with N-MYC in the same complex ([Figure 1](#fig1){ref-type="fig"}D).

Like TFIIIC and RAD21, Aurora-A interacts with N-MYC via two domains flanking MYCBoxI ([@bib37]), raising the possibility that Aurora-A competes with TFIIIC or RAD21 for binding to N-MYC. Indeed, Aurora-A competed with both TFIIIC and RAD21 for binding to the N-MYC N terminus (1--137) in pull-down assays using FLAG-tagged peptides, whereas an equimolar amount of an unrelated protein, glutathione-S-transferase, did not compete ([Figure 1](#fig1){ref-type="fig"}F). Immunoprecipitations from *MYCN*-amplified neuroblastoma cells showed that TFIIIC, RAD21, and Aurora-A were present in α-N-MYC immunoprecipitates ([Figure 1](#fig1){ref-type="fig"}E). In parallel assays, both N-MYC and, weakly, TFIIIC, but not RAD21, were detectable in α-Aurora-A immunoprecipitates ([Figure 1](#fig1){ref-type="fig"}E). We concluded that Aurora-A and RAD21 form alternate complexes with N-MYC in cells, whereas Aurora-A can remain associated with N-MYC and TFIIIC via interactions that are outside of residues N-MYC 1--137 *in vivo*. To identify these domains in N-MYC, we used overlapping peptide libraries in microarray format of N-MYC and probed them with recombinant Aurora-A. Consistent with these and previously published data ([@bib37]), peptides spanning amino acids 17--43 of N-MYC (9--43 in MYC) had the highest affinity for Aurora-A. The arrays also revealed an additional binding site with lower binding affinity for Aurora-A in the C terminus of N-MYC, which spans amino acids 313--339 (overlapping MYCBoxIV) and is conserved in MYC (amino acids 306--331) ([Figure S1](#mmc1){ref-type="supplementary-material"}F).

The interaction of Aurora-A with N-MYC is impaired by mutations of T58 and S62 in N-MYC to alanine ([@bib35]), and immunoprecipitations from infected SH-EP cells confirmed this observation ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Comparison of precipitates recovered from cells expressing N-MYC~wt~ with those from cells expressing N-MYC~mut~ suggested that phosphorylation of MYCBoxI may affect the interaction with TFIIIC ([Figure 1](#fig1){ref-type="fig"}B), but immunoprecipitations from SH-EP cells did not reveal significant differences in the interactions of N-MYC~wt~ and N-MYC~mut~ with RAD21, TFIIIC5, and TOP2A ([Figure S1](#mmc1){ref-type="supplementary-material"}B).

Joint N-MYC/TFIIIC Chromatin Binding Sites {#sec2.2}
------------------------------------------

TFIIIC binds to promoters transcribed by RNA polymerase III and is an architectural protein complex that binds to thousands of ETC (extra TFIIIC) sites throughout the genome that are independent of RNA polymerase III ([@bib31], [@bib34]). To understand whether N-MYC and TFIIIC bind to overlapping sites on chromatin, we performed chromatin immunoprecipitation (ChIP) coupled with high-throughput sequencing (ChIP sequencing) using antibodies directed against N-MYC and TFIIIC5. Inspection of individual genes revealed the presence of both proteins in close vicinity to each other at multiple transcription start sites ([Figure 2](#fig2){ref-type="fig"}A; [Figure S2](#mmc1){ref-type="supplementary-material"}A). Global analyses identified a total of 2,053 sites with overlapping peaks, and statistical analyses showed that this overlap is highly significant ([Figure 2](#fig2){ref-type="fig"}B) (p \< 10^−6^, calculated using a permutation test with 1.0 × 10^6^ iterations). The median distance between peak summits at all joint sites was 39 bp ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Of these sites, 151 were found at tRNA genes; this is expected because MYC proteins bind to tRNA genes ([@bib17]). In addition, overlapping N-MYC/TFIIIC binding sites were found at 1,165 promoters transcribed by Pol II and at 737 intra- and intergenic sites. At core promoters transcribed by Pol II, N-MYC binding peaked at transcription start sites, and TFIIIC binding peaked with a slightly larger median distance of 80 bp 5′ of N-MYC binding sites, suggesting that joint sites may have a defined orientation ([Figure S2](#mmc1){ref-type="supplementary-material"}C).Figure 2Chromatin Binding of N-MYC/TFIIIC Complexes(A) Genome browser tracks at the *NME1* locus illustrating chromatin association of the indicated proteins. The positions of B- and E-boxes and of CTCF motifs are indicated by vertical lines. The upper input is for ChIP sequencing of N-MYC and TFIIIC5; the lower input is for RAD21 and CT*CF.*(B) Top: Venn diagram documenting genome-wide overlap of N-MYC and TFIIIC5 binding sites in IMR-5 neuroblastoma cells. The p value was calculated using a permutation test. Bottom: diagram showing the location of N-MYC/TFIIIC5 sites in the genome.(C) *De novo* motif search in N-MYC- and/or TFIIIC5-bound regions. In overlapping sites, both peak regions were analyzed. The numbers indicate the percentage of sites in which the indicated motif was found. E values for enrichment of the respective motif are shown in [Figure S2](#mmc1){ref-type="supplementary-material"}D. Motifs are only shown if the enrichment was significant.(D) Central enrichment of E-box, CTCF, and AP2a (as a negative control) motifs in the N-MYC peak of N-MYC/TFIIIC5 joint sites in Pol II promoters. The E value is calculated by a binominal test and adjusted for the number of motifs tested.(E) Heatmap showing occupancy of N-MYC, TFIIIC5, RAD21, and CTCF on overlapping N-MYC/TFIIIC sites in IMR-5 cells. Samples are normalized to the same number of mapped reads, and peaks are sorted according to N-MYC binding.(F) Boxplot documenting occupancy of the indicated proteins at joint N-MYC/TFIIIC5 binding sites (n = 1,630) and at N-MYC binding sites lacking TFIIIC5 (n = 2,406) located in promoters of Pol II genes. The number of reads was counted in a region of ± 100 bp around the N-MYC peak summit.See also [Figure S2](#mmc1){ref-type="supplementary-material"}. n indicates the number of independent biological replicas for each experiment.

MYC proteins bind to E-box sequences (CAC(A/G)TG) as part of a heterodimeric complex with MAX ([@bib3]). Consistently, a *de novo* motif search identified E-boxes as a predominant motif enriched in N-MYC binding sites in Pol II promoters and at N-MYC/TFIIIC joint intergenic sites ([Figure 2](#fig2){ref-type="fig"}C; [Figure S2](#mmc1){ref-type="supplementary-material"}D). TFIIIC promotes binding to a sequence termed A-box at tRNA promoters that are not present at ETC sites ([Figure 2](#fig2){ref-type="fig"}C; [Figure S2](#mmc1){ref-type="supplementary-material"}D; [@bib31]). In addition, TFIIIC binds to a sequence termed B-box that is present in tRNA promoters and in ETC sites and the *de novo* motif search confirmed these observations ([Figure 2](#fig2){ref-type="fig"}C; [Figure S2](#mmc1){ref-type="supplementary-material"}D; [@bib31]). B-boxes were also found in overlapping N-MYC/TFIIIC sites in core promoters.

In addition to TFIIIC, ETC sites are also bound by the CTCF transcription factor ([@bib31], [@bib34], [@bib4], [@bib51]). Indeed, a *de novo* motif search analysis identified a centrally enriched consensus motif for CTCF at joint N-MYC/TFIIIC binding sites ([Figures 2](#fig2){ref-type="fig"}C and 2D; [Figures S2](#mmc1){ref-type="supplementary-material"}D--S2F). ChIP sequencing confirmed the presence of CTCF at 936 of 2,053 joint N-MYC/TFIIIC binding sites and showed a much lower occupancy at N-MYC sites that do not bind TFIIIC ([Figures 2](#fig2){ref-type="fig"}E and 2F; [Figure S2](#mmc1){ref-type="supplementary-material"}G). We concluded that N-MYC is present at previously characterized TFIIIC binding sites both in RNA polymerase III promoters and at ETC sites.

N-MYC and TFIIIC Promote Chromatin Association of RAD21 at Joint Binding Sites {#sec2.3}
------------------------------------------------------------------------------

CTCF binding sites define contact points for RAD21/cohesin-mediated chromosomal interactions ([@bib16]). Consistent with this notion, ChIP sequencing showed that RAD21 was present at virtually all (22,642 of 23,479) CTCF-bound sites and at 1,328 of 2,053 joint N-MYC/TFIIIC sites ([Figures 2](#fig2){ref-type="fig"}E and [3](#fig3){ref-type="fig"}A). RAD21 occupancy was much lower at N-MYC sites that do not bind TFIIIC ([Figure 2](#fig2){ref-type="fig"}F). We also observed that endogenous TFIIIC5 robustly co-immunoprecipitated endogenous RAD21 ([Figure 3](#fig3){ref-type="fig"}B). Because RAD21/cohesin complexes do not bind DNA directly, these observations raised the question of whether TFIIIC or N-MYC affects chromatin association of each other and of RAD21. We therefore performed ChIP experiments in cells stably expressing doxycycline-inducible short hairpin RNAs (shRNAs) targeting either TFIIIC or N-MYC. Depletion of TFIIIC5 had little effect on steady-state levels of N-MYC, RAD21, Aurora-A, and the DNA binding subunit TFIIIC2 but led to a small reduction in TFIIIC1 levels ([Figure 3](#fig3){ref-type="fig"}C; [Figure S3](#mmc1){ref-type="supplementary-material"}A; [@bib42]). As expected, we observed reduced binding of TFIIIC5 at multiple N-MYC-bound loci ([Figure 3](#fig3){ref-type="fig"}D). Depletion of TFIIIC5 had no effect on binding of N-MYC but reduced binding of RAD21 at almost all tested joint binding sites, demonstrating that TFIIIC5 promotes binding of RAD21 ([Figure 3](#fig3){ref-type="fig"}D). In contrast, depletion of TFIIIC5 had no effect on RAD21 association with sites that were not bound by TFIIIC and N-MYC ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Notably, shRNA-mediated depletion of TFIIIC5 strongly reduced TFIIIC5 occupancy at sites transcribed by Pol II, but TFIIIC5 binding to tRNA sites was more stable ([Figure S3](#mmc1){ref-type="supplementary-material"}C). Although RAD21 is not detected at tRNA genes ([@bib34], [@bib31]), the stable binding of TFIIIC5 to tRNA encoding genes precluded an unequivocal determination of whether TFIIIC5 promotes binding of N-MYC to tRNA genes. We also depleted TFIIIC2 and found that this has no effect on either N-MYC or RAD21 binding to joint sites, arguing that not all subunits of TFIIIC are limiting for chromatin association of RAD21 ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3D). Depletion of N-MYC using a doxycycline-inducible shRNA reduced binding of N-MYC to most joint sites and significantly reduced binding of both TFIIIC5 and of RAD21 to some sites, although the extent of reduction was more variable than observed after TFIIIC5 depletion ([Figures 3](#fig3){ref-type="fig"}E and 3F). In contrast, depletion of N-MYC did not decrease RAD21 association with sites that were not bound by TFIIIC and N-MYC ([Figure S3](#mmc1){ref-type="supplementary-material"}E). Taken together, the results suggest a hierarchy of chromatin binding in which N-MYC contributes to recruitment of both TFIIIC5 and RAD21 and TFIIIC5 is required for association of RAD21 with joint binding sites.Figure 3Assembly of N-MYC/TFIIIC and RAD21 Complexes on Chromatin(A) Venn diagram documenting genome-wide overlap of N-MYC/TFIIIC5 joint binding sites with RAD21 binding sites. The p value was calculated using a permutation test with 100,000 iterations.(B) Immunoblots of α-TFIIIC5 immunoprecipitates from IMR-5 cells. The input corresponds to 1% of the amount used for the precipitation. Non-specific IgG was used for control immunoprecipitates. Where indicated, CD532 (1 μM) was added to cells 4 hr prior to immunoprecipitation (n = 3).(C) Immunoblot showing levels of the indicated proteins in response to depletion of TFIIIC5. IMR-5 cells expressing an inducible shRNA directed against TFIIIC5 were treated with doxycycline (Dox) for 48 hr or with ethanol (EtOH) as a control (n = 3).(D) ChIP experiments documenting binding of TFIIIC5, N-MYC, and RAD21 to the indicated loci upon depletion of TFIIIC5. Error bars show SD of technical triplicates from one experiment (n = 2).(E) Immunoblot showing levels of the indicated proteins in response to depletion of N-MYC. IMR-5 cells expressing an inducible shRNA directed against N-MYC were treated with Dox for 48 hr or with EtOH as a control (n = 3).(F) ChIP experiments documenting binding of TFIIIC5, N-MYC, and RAD21 to the indicated loci upon depletion of N-MYC. Error bars show SD of technical triplicates from one experiment (n = 2).See also [Figure S3](#mmc1){ref-type="supplementary-material"}. n indicates the number of independent biological replicas for each experiment.

Transcriptional Regulation by N-MYC and TFIIIC/RAD21 {#sec2.4}
----------------------------------------------------

To determine whether TFIIIC5 and RAD21 are required for the transcription of N-MYC target genes, we depleted either protein in IMR-5 cells using specific siRNAs. Control immunoblots are shown in [Figure 4](#fig4){ref-type="fig"}A. RNA sequencing of two independent samples for each protein showed a significant overlap of genes regulated in response to depletion of either protein ([Figure 4](#fig4){ref-type="fig"}B). Gene set enrichment analysis (GSEA) ([@bib47]) showed that multiple well-characterized sets of MYC-activated target genes were significantly downregulated upon depletion of TFIIIC5 or RAD21; in contrast, only few gene sets were significantly upregulated upon depletion of TFIIIC5 or RAD21 ([Figures 4](#fig4){ref-type="fig"}C and 4D). GSEA showed that the most consistently downregulated gene sets encoded proteins involved in cell cycle progression, DNA replication, nucleotide metabolism, and telomere biology ([Figure 4](#fig4){ref-type="fig"}D). Comparison with expression profiles obtained after shRNA-mediated depletion of N-MYC in neuroblastoma cells ([@bib49]) confirmed that expression of these genes is sensitive to depletion of N-MYC ([Figures 4](#fig4){ref-type="fig"}C and 4E). Furthermore, expression of gene sets that are sensitive to depletion of TFIIIC, RAD21, and N-MYC strongly correlated with *MYCN* amplification and advanced tumor stage in neuroblastoma, both of which are characteristic features of aggressive tumors with a poor prognosis ([Figure 4](#fig4){ref-type="fig"}F; [@bib30]). We concluded that TFIIIC and RAD21 are required for expression of a subset of N-MYC target genes that are characteristic for *MYCN*-amplified neuroblastoma tumors. Consistent with these effects on gene expression, shRNA-mediated depletion of TFIIIC5 protein suppressed the growth of neuroblastoma cells ([Figure S4](#mmc1){ref-type="supplementary-material"}A), although it had little effect on the expression of two tRNA genes we tested ([Figure S4](#mmc1){ref-type="supplementary-material"}B). Notably, growth suppression by depletion of TFIIIC5 was independent of *MYCN* amplification ([Figure S4](#mmc1){ref-type="supplementary-material"}A), arguing that TFIIIC5 also has essential functions in non *MYCN*-amplified cells. Most likely, the residual growth of IMR-5 cells after shRNA-mediated depletion of TFIIIC5 was due to incomplete removal of TFIIIC5 because multiple sgRNAs targeting TFIIIC5 eliminated cell growth ([Figure S4](#mmc1){ref-type="supplementary-material"}C). This is consistent with the demonstration that subunits 1--5 of TFIIIC, RAD21, and TOP2A have been identified as essential proteins in genome-wide CRISPR-based loss-of-function screens ([@bib19]). Depletion of TFIIIC5 caused little apoptosis and, like depletion of N-MYC ([@bib35]), delayed progression through all phases of the cell cycle; hence, fluorescence-activated cell sorting (FACS) analyses did not detect a major shift in cell cycle distribution ([Figure S4](#mmc1){ref-type="supplementary-material"}D).Figure 4Gene Regulation by N-MYC, TFIIIC, and RAD21(A) Immunoblots documenting levels of the indicated proteins 48 hr after transfection of specific siRNAs. Duplicate samples are shown, both of which were used for RNA sequencing. All lanes are from the same exposure of a single immunoblot.(B) Venn diagrams documenting the overlap of upregulated (top) and downregulated (bottom) genes after depletion of TFIIIC5 or RAD21 in IMR-5 neuroblastoma cells. The p values were calculated using a Monte Carlo simulation with 100,000 permutations and all expressed genes (n = 17,450) as the basis.(C) Correlation of gene sets that change in expression upon depletion of N-MYC with the aggregate of changes in response to siRNA-mediated depletion of RAD21 and TFIIIC5. Each dot reflects a gene set. A light gray color indicates that the expression change of a gene set was not statistically significant. Published sets of MYC target genes are colored.(D) Examples of gene sets that are downregulated in response to depletion of both RAD21 and TFIIIC5. NES is the normalized enrichment score, indicating direction and extent of regulation.(E) Boxplots documenting changes in expression of selected gene sets upon depletion of N-MYC using a Dox-inducible shRNA in IMR-32 neuroblastoma cells.(F) Heatmap illustrating stage-specific expression of N-MYC/TFIIIC/RAD21-regulated genes sets in human neuroblastoma cells. The black bars in the first row indicate *MYCN* amplification status.See also [Figure S4](#mmc1){ref-type="supplementary-material"}. n indicates the number of independent biological replicas for each experiment.

Cell Cycle-Dependent Regulation of N-MYC Binding and Chromatin Association {#sec2.5}
--------------------------------------------------------------------------

Aurora-A has been implicated in cell cycle progression, prompting us to analyze complex formation between N-MYC and Aurora-A throughout the cell cycle in a semiquantitative manner using proximity ligation assays (PLAs) ([@bib45]). In PLAs, a rolling circle amplification using oligonucleotides bound to secondary antibodies generates a signal that appears as a fluorescent dot when two antigens are in proximity of each other. Controls using a N-MYC antibody in SH-EP cells that do not express N-MYC ([Figure S5](#mmc1){ref-type="supplementary-material"}A) or using no primary antibody ([Figure S5](#mmc1){ref-type="supplementary-material"}B) established that the signals observed in these assays are specific. We used either a release from a double thymidine block ([Figure S5](#mmc1){ref-type="supplementary-material"}C) or re-stimulation of serum-starved cells ([Figure S5](#mmc1){ref-type="supplementary-material"}D) to synchronize cells. In both experimental settings, Aurora-A predominantly associated with N-MYC during the S phase of the cell cycle, and complex formation was regulated independently of changes in overall N-MYC and Aurora-A protein levels ([Figures 5](#fig5){ref-type="fig"}A, 5B, and 5E; [Figures S5](#mmc1){ref-type="supplementary-material"}E and S5F). We next tested whether association of N-MYC with cofactors changes throughout the cell cycle. Neither the association of N-MYC with p400 and TRRAP, which is mediated by MYCBoxII (amino acids 128--143), nor the interactions with the PAF1 components CTR9 and CDC73, for which the interaction domains are unknown, varied throughout the cell cycle ([Figure S5](#mmc1){ref-type="supplementary-material"}G). In contrast, association of RAD21 with N-MYC was essentially absent during S phase ([Figures 5](#fig5){ref-type="fig"}C--5E). Similarly, associations of N-MYC with TOP2A and TFIIIC5 changed during cell cycle progression and were significantly lower in S phase ([Figures 5](#fig5){ref-type="fig"}C--5E; [Figure S5](#mmc1){ref-type="supplementary-material"}H). ChIP experiments from cells harvested in G1 and S phase showed that association of N-MYC with joint binding sites was essentially equal in both cell cycle phases, whereas chromatin association of RAD21 was strongly reduced in S relative to G1 phase ([Figure 5](#fig5){ref-type="fig"}F). Chromatin association of TFIIIC was also reduced in S phase, but the extent of decrease was more variable between different gene loci. We concluded that complex formation of N-MYC with RAD21, TFIIIC, and TOP2A and chromatin binding of RAD21 and TFIIIC are reduced during S phase.Figure 5Regulation of N-MYC Transcription Complexes during the Cell Cycle(A) Representative pictures from proximity ligation assays (PLAs) documenting complex formation between N-MYC and Aurora-A in IMR-5 cells after release from a double thymidine block. Non-synchronized cells are shown as a control (Ctr). Nuclei were stained using Hoechst. Red dots show PLA signals resulting from N-MYC/Aurora-A interactions (n = 3).(B) Quantification of the PLA shown in (A). The percentage of cells in S phase is indicated in parallel. Error bars show SD of technical triplicates from one representative experiment (n = 3).(C) Representative FACS profiles of propidium iodide (PI)-stained cells documenting cell cycle distribution at the indicated times after release from a double thymidine block.(D) Representative pictures from PLAs documenting complex formation between N-MYC and RAD21 and TOP2A and TFIIIC5 in IMR-5 cells at the indicated times after release from a double thymidine block. Nuclei were stained using Hoechst. Red dots show PLA signals (n = 3).(E) Quantification of PLAs shown in (A) and (D). Bars show mean + SD of technical triplicates from one representative experiment (n = 3). ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.(F) ChIP of IMR-5 cells documenting chromatin association of N-MYC, RAD21, and TFIIIC5 at the indicated gene loci at the indicated times after release from a double thymidine block. Error bars show SD of technical triplicates from one representative experiment (n = 3).See also [Figure S5](#mmc1){ref-type="supplementary-material"}. n indicates the number of independent biological replicas for each experiment.

Aurora-A Antagonizes N-MYC/RAD21 Complex Formation in S Phase {#sec2.6}
-------------------------------------------------------------

We showed previously that association with N-MYC activates the catalytic activity of Aurora-A ([@bib37]), and large-scale proteomic analyses show that multiple proteins associated with N-MYC, including TFIIIC2 and TOP2A, are phosphorylated in an Aurora-A-dependent manner *in vivo* ([@bib22]). These findings, and the observation that Aurora-A competes with association of RAD21 with N-MYC, led us to hypothesize that Aurora-A may antagonize complex formation of N-MYC with RAD21, TOP2A, and, potentially, TFIIIC during S phase. To test this, we used three structurally well-characterized Aurora-A inhibitors to acutely antagonize Aurora-A ([Figure 6](#fig6){ref-type="fig"}A; [@bib37]). Of the inhibitors used, MK-5108 is a purely catalytic Aurora-A inhibitor that does not alter the conformation of Aurora-A and does not affect complex formation with N-MYC. MLN8237 inhibits both the catalytic activity of Aurora-A and moderately distorts the N-MYC/Aurora-A complex, enhancing degradation of N-MYC by FBXW7 in mitosis. CD532 strongly distorts the Aurora-A structure, dissociates the N-MYC/Aurora-A complex, and induces subsequent degradation of Aurora-A and N-MYC ([@bib37]). We confirmed that CD532 causes a proteasome-dependent decrease in N-MYC and Aurora-A levels ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B). In contrast, CD532 had no effect on complex formation of TFIIIC5 with RAD21 ([Figure 3](#fig3){ref-type="fig"}B).Figure 6Role of Aurora-A in Dynamics of N-MYC Complexes during the Cell Cycle(A) Immunoblot documenting levels of the indicated proteins and of Aurora-A, which is autophosphorylated at T288 (indicating catalytically active Aurora-A), in IMR-5 *MYCN-*amplified neuroblastoma cells after 4 hr (left) or 24 hr (right) exposure to 1 μM of the indicated Aurora-A inhibitors (n = 4).(B) Representative pictures from PLAs documenting complex formation between N-MYC and RAD21 and TOP2A or TFIIIC5 in IMR-5 cells released for 4 hr from a double thymidine block in the presence of the indicated Aurora-A inhibitors (1 μM) or DMSO as a control. Nuclei were stained using Hoechst. Red dots show signals arising from interaction of N-MYC with the indicated proteins.(C) Quantification of PLAs shown in (B). Data are normalized to DMSO-treated cells. Bars show mean + SD of technical triplicates from one experiment (n = 4). ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.(D) Genome browser tracks at the *PPRC1* locus, illustrating chromatin association of the indicated proteins. The positions of B- and E-boxes and of CTCF motifs are indicated by vertical lines. The upper input is for ChIP sequencing of N-MYC and TFIIIC5, the lower input is for ChIP-sequencing of RAD21 and CTCF.(E) ChIP of IMR-5 cells documenting chromatin association of N-MYC, TFIIIC5, and RAD21 at the indicated loci after treatment (1 μM) with MK-5108 (24 hr), MLN8237 (24 hr), CD532 (4 hr), or DMSO as a control. Error bars show SEM of three independent experiments. Data are normalized to DMSO-treated cells.See also [Figure S6](#mmc1){ref-type="supplementary-material"}. n indicates the number of independent biological replicas for each experiment.

PLA assays from cells released for 4 hr from a double thymidine block into S phase showed that MK-5108 and MLN8237 enhanced interactions of N-MYC with TFIIIC5, TOP2A, and, albeit more weakly, RAD21 ([Figures 6](#fig6){ref-type="fig"}B and 6C). In these assays, MK-5108 had the strongest effect. CD532 and MLN8237 had smaller and more variable effects in PLAs with TOP2A, RAD21, and TFIIIC5, most likely because the observed signals reflect a combination of the decrease in N-MYC levels and an increase in interaction ([Figures 6](#fig6){ref-type="fig"}A--6C). The data argue that Aurora-A-dependent phosphorylation antagonizes interactions of N-MYC with all three proteins.

ChIP and ChIP sequencing showed that chromatin association of N-MYC decreased in response to CD532, consistent with the effects on protein levels ([Figures 6](#fig6){ref-type="fig"}D and 6E; [Figure S6](#mmc1){ref-type="supplementary-material"}C). In contrast, CD532 globally increased TFIIIC binding to chromatin ([Figure 6](#fig6){ref-type="fig"}D; [Figure S6](#mmc1){ref-type="supplementary-material"}D), and the number of joint N-MYC/TFIIIC binding sites increased to 7,994 in the presence of CD532 ([Figure S6](#mmc1){ref-type="supplementary-material"}E; note that N-MYC binding to chromatin remains detectable at virtually all sites after 4 hr of CD532 treatment). ChIP assays confirmed that CD532 enhanced stable chromatin binding of TFIIIC and RAD21 at joint binding sites, whereas the effects of MLN8237 and MK-5108 were weak for most sites ([Figure 6](#fig6){ref-type="fig"}E). We concluded that a decrease in Aurora-A levels or dissociation of N-MYC/Aurora-A complexes promotes stable association of TFIIIC and RAD21 with N-MYC-bound loci in S phase; it is also possible that inhibition of Aurora-A-dependent TFIIIC2 phosphorylation contributes to the increase. Notably, chromatin association of TFIIIC also increased in response to CD532 on sites where no N-MYC peak was detected in ChIP sequencing ([Figure S6](#mmc1){ref-type="supplementary-material"}E). It is possible, therefore, that Aurora-A inhibits TFIIIC binding to chromatin also when complexed by other transcription factors. However, removing the inherent threshold in peak-calling algorithms revealed the presence of N-MYC at the majority (26,165 of 36,736) of all TFIIIC sites detectable after CD532 treatment ([Figure S6](#mmc1){ref-type="supplementary-material"}F). Most likely, therefore, N-MYC is associated with the majority of all TFIIIC sites.

Cell Cycle-Dependent Regulation of Pause Release by Aurora-A {#sec2.7}
------------------------------------------------------------

To understand the role of TFIIIC in N-MYC-dependent pause release of Pol II, we analyzed SH-EP neuroblastoma cells, which express an N-MYCER chimeric protein that can be activated by addition of 4-Hydroxytamoxifen (4-OHT). We engineered these cells to express a doxycycline-inducible shRNA targeting TFIIIC5 ([Figure 7](#fig7){ref-type="fig"}A) and performed ChIP sequencing with antibodies directed against total Pol II before and 5 hr after addition of 4-OHT. Inspection of individual genes (*ODC1* and *NPM1*) ([Figure S7](#mmc1){ref-type="supplementary-material"}A) and global analyses ([Figures 7](#fig7){ref-type="fig"}B and 7C; [Figure S7](#mmc1){ref-type="supplementary-material"}B) showed that activation of N-MYC led to a strong decrease in Pol II occupancy at the transcription start site and a corresponding decrease in the Pol II "traveling ratio," which is defined as the ratio of Pol II occupancy at the promoter to occupancy in the gene body ([@bib36]). Depletion of TFIIIC5 by itself caused a moderate increase in Pol II promoter occupancy and Pol II traveling ratio ([Figures 7](#fig7){ref-type="fig"}B and 7C; [Figures S7](#mmc1){ref-type="supplementary-material"}A and S7B). Intriguingly, depletion of TFIIIC5 abrogated the effect of N-MYCER on Pol II ([Figures 7](#fig7){ref-type="fig"}B and 7C; [Figures S7](#mmc1){ref-type="supplementary-material"}A and S7B).Figure 7Aurora-A Suppresses N-MYC-Dependent Pause Release of Pol II in S phase(A) Immunoblot showing levels of TFIIIC5 in SH-EP-N-MYCER cells expressing a Dox-inducible shRNA targeting TFIIIC5 (n = 3). Dox (1 μg ml^−1^) was added for 30 hr; EtOH was used as a control.(B) Metagene plot of all expressed genes (n = 14,650) illustrating distribution of Pol II within transcribed regions before and 5 hr after activation of N-MYCER in cells expressing Dox-inducible shTFIIIC5.(C) 2D kernel density plot showing the ratio of Pol II occupancy at the promoter to occupancy in the gene body (traveling ratio) in cells treated as above for all expressed genes (n = 14,650) before and after 5 hr of N-MYCER-activation.(D). ChIP of SH-EP N-MYCER cells documenting chromatin association of hypo-phosphorylated Pol II and Pol II phosphorylated at Ser5 (pSer5) or Ser2 (pSer2) at the indicated gene loci before and 5 hr after activation of N-MYCER. Occupancy at the transcription start site (TSS) was analyzed for hypo-phosphorylated Pol II and pSer5Pol II. Occupancy at the transcription end site (TES) was analyzed for pSer2Pol II. Dox (1 μg ml^−1^) was added for 30 hr; EtOH was used as a control. Error bars show SD of technical triplicates from one representative experiment (n = 3).(E) Genome browser tracks illustrating chromatin association of Pol II and Pol II pSer2 at the *ODC1* locus. ChIP sequencing was performed on cells synchronized in S phase by double thymidine blockade and treated for 2 hr with CD532 where indicated (1 μM).(F) 2D kernel density plot showing the Pol II traveling ratio in response to N-MYCER activation in SH-EP cells that were synchronized in S phase by double thymidine block for all expressed genes (n = 14,650) before and after 4 hr of N-MYCER activation.(G) Model summarizing our findings. We propose that the multiple protein-protein interactions of N-MYC promote sequential phosphorylation events of Pol II and both promotor escape and pause release. The dashed line indicates that effects on pause release and Ser2 phosphorylation could be secondary to changes in Ser5 phosphorylation. E/C indicates that the complex associates with sites on chromatin that contain either an E-box or a CTCF motif.See also [Figure S7](#mmc1){ref-type="supplementary-material"}. n indicates the number of independent biological replicas for each experiment.

To understand which of N-MYC's effects on Pol II depend on TFIIIC, we performed ChIPs using antibodies that specifically recognize hypo-phosphorylated Pol II (8WG16) ([@bib46]) or Pol II phosphorylated at Ser5, which occurs during escape of Pol II from the promoter, or at Ser2, which is a hallmark of pause release of Pol II, respectively. Intriguingly, ChIP sequencing showed that activation of N-MYC had no significant effect on chromatin association of hypo-phosphorylated Pol II ([Figure S7](#mmc1){ref-type="supplementary-material"}C). To pinpoint the effect of N-MYC on Pol II function, we analyzed the association of Pol II with several MYC target genes for which Pol II does not decrease strongly at the promoter after N-MYC activation. Consistent with the ChIP sequencing data, neither activation of N-MYC nor depletion of TFIIIC5 had a significant effect on the association of hypo-phosphorylated Pol II with the transcription start site of several N-MYC target genes ([Figure 7](#fig7){ref-type="fig"}D). In contrast, depletion of TFIIIC5 abrogated both an N-MYC-dependent increase of Pol II that is phosphorylated at Ser5 at the transcription start site and of Pol II phosphorylated at Ser2 at the transcription end site ([Figure 7](#fig7){ref-type="fig"}D). Collectively, the data argue that TFIIIC5 is required for N-MYC-dependent escape of Pol II from the promoter and the subsequent pause release of Pol II.

To understand whether N-MYC-dependent pause release is cell cycle-regulated and whether Aurora-A affects this process, we activated N-MYCER in cells synchronized in S phase by a double thymidine block ([Figures 7](#fig7){ref-type="fig"}E and 7F). Under these circumstances, activation of N-MYC did not promote pause release of Pol II; rather, activation of N-MYC caused a slight global increase in Pol II occupancy at core promoters, consistent with observations that MYC proteins can enhance promoter association of Pol II ([@bib20]). To test whether Aurora-A is required to block N-MYC-dependent pause release in S phase, we added CD532 to synchronized cells and performed ChIP sequencing both in the presence and absence of 4-OHT. Addition of CD532 to cells with activated N-MYC globally enhanced association of Pol II with the body of transcribed genes ([Figure 7](#fig7){ref-type="fig"}E; [Figure S7](#mmc1){ref-type="supplementary-material"}D). In contrast, CD532 had little effect on Pol II function in cells with inactive N-MYCER, arguing that the effects on Pol II are mediated via N-MYC ([Figure 7](#fig7){ref-type="fig"}E; [Figure S7](#mmc1){ref-type="supplementary-material"}D). CD532 also enhanced association of Pol II with the promoter in a N-MYC-dependent manner and, as consequence, did not alter the overall traveling ratio ([Figure S7](#mmc1){ref-type="supplementary-material"}E). Furthermore, CD532 increased chromatin association of pSer2-Pol II in the gene body and at the transcription end site, and the effect was stronger in the presence of active N-MYC ([Figure 7](#fig7){ref-type="fig"}E). We concluded that association with Aurora-A antagonizes N-MYC-dependent promoter binding of Pol II and transcriptional elongation during S phase.

Finally, we explored a possible effect of enhanced transcriptional elongation on DNA replication and monitored phosphorylation of the single-strand DNA binding protein RPA32 at S33, which is phosphorylated by the ATR kinase in response to replication stress ([Figure S7](#mmc1){ref-type="supplementary-material"}F; [@bib26]). Inhibition of Aurora-A during the release of IMR-5 cells from a double thymidine block markedly enhanced phosphorylation of this site. In contrast, we did not observe phosphorylation of RPA32 at S4 and S8, target sites of DNA-dependent protein kinase (DNA-PK), and no activation of CHK1 and stabilization of p53 ([Figure S7](#mmc1){ref-type="supplementary-material"}F). Consistently, inhibition of Aurora-A perturbed S phase progression, but did not prevent S phase entry or induce apoptosis ([Figure S7](#mmc1){ref-type="supplementary-material"}G; [Discussion](#sec3){ref-type="sec"}). A model summarizing our findings is shown in [Figure 7](#fig7){ref-type="fig"}G.

Discussion {#sec3}
==========

We performed a proteomic analysis of N-MYC complexes in neuroblastoma cells and confirmed previously identified interactions of MYC and N-MYC proteins with MAX, the NuA4 complex, BPTF, p400, and the PAF1 complex. We also validated TFIIIC, RAD21, and TOP2A as interaction partners of N-MYC, arguing that N-MYC uses multiple effector proteins to regulate transcription. Previous proteomic analyses demonstrated the presence of TFIIIC and TOP2A in MYC complexes, suggesting that these interactions are conserved with MYC proteins ([@bib23]).

Our data provide insights into how MYC accelerates several transitions of Pol II from one intermediate promoter state to the next. TFIIIC is both a general transcription factor of RNA polymerase III and an architectural protein ([@bib50]) and has been linked to the function of both cohesin and condensin complexes. In yeast, TFIIIC is required for loading condensin complexes onto tRNA genes ([@bib10]). In *Drosophila*, TFIIIC co-localizes with RAD21/cohesin at ETC sites ([@bib50]). Our ChIP sequencing data showed that N-MYC co-localizes with TFIIIC at multiple promoters and intergenic sites. TFIIIC is essential for transcription by RNA polymerase III, but the precise function of TFIIIC at ETC sites is unknown. We found that TFIIIC5 promotes association of RAD21 with N-MYC-bound promoters and is required for N-MYC-dependent phosphorylation of Pol II at Ser5 and Ser2 at several target genes, arguing that it promotes both promoter escape and pause release of Pol II. ChIP experiments suggest a hierarchy in which N-MYC promotes binding of TFIIIC, and TFIIIC, in turn, recruits RAD21. Because RAD21 and cohesin can promote pause release of Pol II ([@bib41]), we suggest that N-MYC-dependent recruitment of RAD21 via TFIIIC facilitates promoter escape and pause release of Pol II in an enhancer-dependent manner. The model is consistent with the recent observation that depletion of RAD21 represses expression of N-MYC and MYC target genes ([@bib39]). Because the identity of active enhancers is characteristic for each cell, a model in which N-MYC facilitates the function of pre-existing enhancers could explain how N-MYC can "amplify" a pre-existing gene expression program.

Topoisomerase I is activated at core promoters via direct association with Pol II and promotes pause release because it relieves the torsional stress that builds up during early stages of transcription ([@bib1]). Because TOP2A associates with promoters of highly transcribed genes ([@bib24]), it is likely that the association with N-MYC similarly relieves torsional stress during early stages of transcription, suggesting that multiple protein-protein interactions enable MYC proteins to facilitate consecutive steps of transcription ([Figure 7](#fig7){ref-type="fig"}G).

Unexpectedly, complexes of N-MYC are highly dynamic during the cell cycle. *In vitro*, Aurora-A competes with binding of TFIIIC and RAD21 to the amino-terminus of N-MYC. A secondary binding site for Aurora-A overlaps with MYCBoxIV, which binds to HCF1, and it is possible, therefore, that Aurora-A also competes with HCF1 for binding to N-MYC ([@bib48]). *In vivo*, Aurora-A inhibits chromatin binding of TFIIIC and RAD21 and interactions of N-MYC with RAD21, TOP2A, and TFIIIC in S phase ([Figure 7](#fig7){ref-type="fig"}G). N-MYC-dependent pause release is inhibited in S phase, and inhibition of Aurora-A using CD532 partially restores elongation. Why might this regulation be important? Inhibition of Aurora-A during S phase activates the ATR kinase, which monitors replication stress ([@bib18]). Phosphorylation of RPA32 at S33 with no CHK1 phosphorylation, as observed here, has been linked to recovery of collapsed replication forks rather than CHK1-mediated cell cycle arrest and DNA repair ([@bib43]). We hypothesize, therefore, that MYC-dependent transcriptional elongation has an inherent potential to cause conflicts with DNA replication and that complex formation of N-MYC with Aurora-A is one of several co-transcriptional mechanisms that prevent such conflicts ([@bib18]). Notably, TFIIIC binding was detected at many sites on chromatin at which we did not detect N-MYC, and TFIIIC binding was regulated by Aurora-A also at such sites. It is possible, therefore, that Aurora-A also regulates TFIIIC chromatin association independently of N-MYC. However, removing the inherent threshold in peak calling revealed the presence of N-MYC at the majority of all TFIIIC sites.

Inhibition of Aurora-A shows therapeutic efficacy in multiple MYC- and N-MYC-driven tumor models ([@bib12], [@bib13]). Similarly, deregulated expression of MYC and N-MYC activates ATR, and inhibition of ATR or CHK1 are being explored as possible therapeutic strategies for MYC- and N-MYC-driven tumors ([@bib6], [@bib32]). Our findings suggest that MYC-driven tumors are particularly dependent on Aurora-A to avoid transcription/replication conflicts and open the possibility for rational development of therapies targeting these tumors.

Experimental Procedures {#sec4}
=======================

Further details and an outline of the resources used in this work can be found in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Cell Culture and Cell Cycle Synchronization {#sec4.1}
-------------------------------------------

Neuroblastoma cell lines (IMR-5, IMR-32, and SH-EP) were grown in RPMI-1640 supplemented with 10% fetal calf serum and penicillin/streptomycin. For synchronization in S phase, cells were treated for 16 hr with 2 mM thymidine, released for 8 hr into normal medium, and then blocked again (2 mM, 16 hr). For release, cells were washed with PBS before fresh medium was added.

High-Throughput Sequencing {#sec4.2}
--------------------------

ChIP and ChIP sequencing were performed as described previously ([@bib52]). RNA sequencing was performed as described previously ([@bib20]) using an Illumina NextSeq 500. Preparations of samples, data quality assessment, filtering, and mapping are described in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

*In Situ* PLA {#sec4.3}
-------------

The PLA was performed using the Duolink *In Situ* Kit (Sigma-Aldrich) according to the manufacturer's protocol. Pictures were taken with a confocal microscope (Nikon Ti-Eclipse) at 60× magnification. For quantification, the dots in not less than 300 cells were counted using ImageJ (Wayne Rasband, NIH). Antibodies are listed in the resource table in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Statistical Methods {#sec4.4}
-------------------

Statistical significance between experimental groups was determined by Student's t test or, when means of three or more groups were compared, by one-way ANOVA. Data analysis was performed with Prism5.0 software (GraphPad). p \< 0.05 was considered statistically significant.

Data and Software Availability {#app1}
==============================

The accession number for the RNA and ChIP sequencing data reported in this paper is GEO: [GSE78957](ncbi-geo:GSE78957){#intref0010}.
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